MAYNE PHARMA GROUP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.93 AUD | -2.39% |
|
+4.05% | +12.68% |
| Feb. 26 | Mayne Pharma Group Swings to Loss in Fiscal H1 Despite Revenue Growth; Shares Jump 15% | MT |
| Feb. 25 | Transcript : Mayne Pharma Group Limited, H1 2024 Earnings Call, Feb 26, 2024 |
Valuation
| Fiscal Period: Junio | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 807.3 | 646.4 | 564.7 | 441.2 | 366.6 | 562.4 | - | - |
| Enterprise Value (EV) 1 | 1,088 | 906.7 | 813.6 | 758.2 | 321.5 | 490.3 | 501.4 | 484.3 |
| P/E ratio | -2.68 x | -6.34 x | -2.41 x | -1.56 x | 2.97 x | -6.77 x | -202 x | 31.7 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 1.54 x | 1.41 x | 1.41 x | 1.04 x | 2 x | 1.46 x | 1.31 x | 1.14 x |
| EV / Revenue | 2.07 x | 1.98 x | 2.03 x | 1.78 x | 1.75 x | 1.28 x | 1.17 x | 0.98 x |
| EV / EBITDA | 8.31 x | 9.51 x | 12.8 x | 16.6 x | -3.37 x | 20.7 x | 7.71 x | 4.64 x |
| EV / FCF | 11,486,336 x | 20,651,950 x | 19,477,342 x | -44,043,229 x | -6,298,425 x | - | - | - |
| FCF Yield | 0% | 0% | 0% | -0% | -0% | - | - | - |
| Price to Book | 0.8 x | 0.62 x | 0.73 x | 0.78 x | 0.58 x | 1.07 x | 1.16 x | 1.18 x |
| Nbr of stocks (in thousands) | 79,147 | 83,953 | 88,242 | 88,242 | 83,324 | 81,148 | - | - |
| Reference price 2 | 10.20 | 7.700 | 6.400 | 5.000 | 4.400 | 6.930 | 6.930 | 6.930 |
| Announcement Date | 8/22/19 | 8/20/20 | 8/26/21 | 8/25/22 | 8/30/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Junio | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 525.2 | 457 | 400.8 | 424.8 | 183.6 | 384.3 | 429.5 | 492.8 |
| EBITDA 1 | 130.9 | 95.3 | 63.5 | 45.7 | -95.3 | 23.69 | 65.04 | 104.5 |
| EBIT 1 | 37.2 | 11.7 | -3.7 | -34.5 | -160.7 | -46.66 | -19.82 | 28.07 |
| Operating Margin | 7.08% | 2.56% | -0.92% | -8.12% | -87.53% | -12.14% | -4.62% | 5.7% |
| Earnings before Tax (EBT) | -353.7 | -135.4 | -263.9 | - | - | - | - | - |
| Net income 1 | -280.9 | -92.8 | -208.4 | -263.3 | 117.2 | -83.7 | -2.791 | 17.76 |
| Net margin | -53.48% | -20.31% | -52% | -61.99% | 63.87% | -21.78% | -0.65% | 3.6% |
| EPS 2 | -3.808 | -1.214 | -2.652 | -3.200 | 1.480 | -1.023 | -0.0344 | 0.2186 |
| Free Cash Flow | 94.69 | 43.9 | 41.77 | -17.22 | -51.05 | - | - | - |
| FCF margin | 18.03% | 9.61% | 10.42% | -4.05% | -27.81% | - | - | - |
| FCF Conversion (EBITDA) | 72.34% | 46.07% | 65.78% | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 8/22/19 | 8/20/20 | 8/26/21 | 8/25/22 | 8/30/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: Junio | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2025 S1 | 2025 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 227.2 | 229.8 | 208.8 | 192 | 195.6 | 228.4 | - | 82.42 | 187.9 | 201 | 202.7 |
| EBITDA | 47.4 | 47.9 | 39.9 | 23.6 | 23.7 | 22 | - | -42.2 | - | - | - |
| EBIT | -12.3 | 24 | 2.3 | -6 | -17.6 | -16.9 | - | - | - | - | - |
| Operating Margin | -5.41% | 10.44% | 1.1% | -3.13% | -9% | -7.4% | - | - | - | - | - |
| Earnings before Tax (EBT) | -24.96 | -110.4 | -229.3 | -34.63 | -63.7 | -154.1 | - | - | - | - | - |
| Net income | -17.5 | -75.3 | -181.3 | -27.11 | -50.4 | -213 | 290 | - | -70.55 | - | - |
| Net margin | -7.7% | -32.77% | -86.81% | -14.12% | -25.77% | -93.26% | - | - | -37.54% | - | - |
| EPS | -0.2400 | - | -2.320 | -0.3320 | -0.6200 | -2.580 | 0.1760 | - | -0.8780 | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/20/20 | 8/20/20 | 2/23/21 | 8/26/21 | 2/24/22 | 8/25/22 | 2/27/23 | 8/30/23 | 2/25/24 | - | - |
1AUD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: Junio | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 280 | 260 | 249 | 317 | - | - | - | - |
| Net Cash position 1 | - | - | - | - | 45.1 | 72.1 | 60.9 | 78 |
| Leverage (Debt/EBITDA) | 2.142 x | 2.731 x | 3.919 x | 6.936 x | - | - | - | - |
| Free Cash Flow | 94.7 | 43.9 | 41.8 | -17.2 | -51 | - | - | - |
| ROE (net income / shareholders' equity) | 1.26% | -1.25% | -3.14% | -18.8% | - | - | - | - |
| ROA (Net income/ Total Assets) | 0.81% | -0.74% | -1.73% | -9.13% | - | - | - | - |
| Assets 1 | -34,530 | 12,520 | 12,071 | 2,883 | - | - | - | - |
| Book Value Per Share 2 | 12.70 | 12.40 | 8.710 | 6.400 | 7.600 | 6.450 | 6.000 | 5.900 |
| Cash Flow per Share 2 | 1.450 | 1.260 | 0.7100 | -0.0900 | -0.5200 | -0.6900 | 0.4400 | 0.8000 |
| Capex 1 | 11.9 | 8.99 | 17.1 | 10 | 8.34 | 8.67 | 12.6 | 11.3 |
| Capex / Sales | 2.27% | 1.97% | 4.26% | 2.36% | 4.54% | 2.26% | 2.93% | 2.3% |
| Announcement Date | 8/22/19 | 8/20/20 | 8/26/21 | 8/25/22 | 8/30/23 | - | - | - |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6.93
AUD
Average target price
7.035
AUD
Spread / Average Target
+1.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.68% | 367M | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- MYX Stock
- Financials Mayne Pharma Group Limited
